About Us

Actinogen Medical  (ACW) is an ASX-listed, biotechnology company developing an innovative treatment for cognitive impairment associated with neurological diseases amenable to modifications of raised cortisol levels inside brain cells. ‘Cognition’ relates to how a person understands and acts in the world around them. Cognitive functions include memory, reasoning, awareness and decision-making, and to a large extent, influence our personality.

Actinogen Medical’s lead drug candidate, Xanamem®has been specifically designed to block the production of cortisol – the stress hormone – in the brain. Chronically elevated cortisol is associated with cognitive decline in Alzheimer’s Disease, potentially linked to cognitive impairment and anxiety in Fragile X syndrome, and cognitive impairment in other diseases. 

Xanamem offers a promising new approach to treat cognitive impairment associated with these neurological diseases.

In the Company’s recent XanaHES Phase I trial, Xanamem exhibited a statistically significant improvement in cognition among healthy older volunteers treated with 20mg Xanamem daily, and recent human target engagement data for the drug in the brain suggests good activity of doses as low as 5mg daily. The Company plans to initiate a range of Phase II studies evaluating Xanamem in the treatment of cognitive impairment associated with Alzheimer’s disease, Fragile X syndrome, and other indication(s) with a strong scientific rationale.

Our Team

BOARD OF DIRECTORS

DR. GEOFF BROOKE

NON-EXECUTIVE CHAIRMAN

DR. GEOFF BROOKE

Dr Brooke is a clinically trained physician turned venture capitalist with over 30 years' experience in the healthcare investment industry.
Read More

DR. GEORGE MORSTYN

NON-EXECUTIVE DIRECTOR

DR. GEORGE MORSTYN

Dr Morstyn has more than 25 years’ experience in the biotechnology industry including as Senior Vice President of Development and Chief Medical Officer at Amgen Inc.
Read More

MALCOLM McCOMAS

NON-EXECUTIVE DIRECTOR

MALCOLM McCOMAS

Mr. McComas brings 25 years of investment banking experience in M&A, debt and equity funding across multiple industry sectors.
Read More

DR. STEVEN GOURLAY

CHIEF EXECUTIVE OFFICER & MANAGING DIRECTOR

DR. STEVEN GOURLAY

Dr Gourlay has more than 30 years’ experience in the development of novel therapeutics and has significant drug regulatory experience interacting with the FDA and EMA.
Read More

MANAGEMENT TEAM

DR. STEVEN GOURLAY

CHIEF EXECUTIVE OFFICER & MANAGING DIRECTOR

DR. STEVEN GOURLAY

Dr Gourlay has more than 30 years’ experience in the development of novel therapeutics and has significant drug regulatory experience interacting with the FDA and EMA.
Read More

PETER WEBSE

COMPANY
SECRETARY

PETER WEBSE

Mr Webse has over 26 years of company secretarial experience and is the managing director of Platinum Corporate Secretariat Pty Ltd.
Read More

JEFF CARTER

CHIEF FINANCIAL
OFFICER

JEFF CARTER

Mr Carter has more than 30 years of expertise in professional accounting, investment banking, corporate finance and commercial / strategic planning roles.
Read More

TAMARA MILLER

VICE PRESIDENT DRUG DEVELOPMENT & STRATEGY

TAMARA MILLER

Tamara joined Actinogen in September 2017, bringing with her over 18 years of international clinical research experience.
Read More

KATE LINGARD

ASSOCIATE DIRECTOR OF CLINICAL OPERATIONS

KATE LINGARD

Kate has a wealth of experience in Clinical Operations in both Biotechnology companies and Contract Research Organisations.
Read More

MIRIAM ROESNER

CLINICAL DEVELOPMENT MANAGER

MIRIAM ROESNER

Miriam has over 16 years of experience working in Biotechnology and CRO settings.
Read More

DR. JACK TAYLOR

CLINICAL SCIENTIST

DR. JACK TAYLOR

Jack joined Actinogen in February 2020, bringing a deep understanding of pharmaceutical science and a passion for novel drug discovery research.
Read More

THERESE RUSSELL

EXECUTIVE ASSISTANT & OFFICE MANAGER

THERESE RUSSELL

Therese joined the team in 2016, bringing with her over 20 years of experience in administrative and office management.
Read More

Xanamem Clinical Advisory Board

Prof Craig Ritchie

(CHAIR)

Prof Craig Ritchie

Professor Ritchie is a world-leading authority on dementia and has been a senior investigator on more than 30 drug trials of both disease-modifying and symptomatic agents for the condition.
Read More

PROF COLIN MASTERS AO

PROF COLIN MASTERS AO

Professor Masters' research career in Alzheimer’s disease and other neurodegenerative diseases spans over 35 years. He is widely acknowledged as a major worldwide influencer on Alzheimer’s disease research.
Read More

PROF JEFFREY CUMMINGS

PROF JEFFREY CUMMINGS

Professor Cummings is a world-renowned Alzheimer’s researcher and leader of clinical trials.
Read More

Scientific Advisory Board

PROF ALAN BOYD

PROF ALAN BOYD

Professor Boyd began his 30 year pharmaceutical career with Glaxo Group Research Ltd. He has held senior or management roles in many global pharmaceutical companies.
Read More

PROF BRIAN R WALKER

PROF BRIAN R WALKER

Professor Walker's prolific research over 20 years has concerned the role of glucocorticoids in metabolic syndrome and cardiovascular disease.
Read More

PROF SCOTT WEBSTER

PROF SCOTT WEBSTER

Professor Webster has held positions in both biotech and academia and his research has led to the discovery of a number of potent small molecule modulators of target enzymes and receptors, including UE2343/Xanamem.
Read More

PROF JONATHAN SECKL

PROF JONATHAN SECKL

Professor Jonathan Seckl is an academic endocrinologist (MBBS UCL, PhD London).
Read More